非诺贝特治疗高脂血症40例疗效观察

目的：观察非诺贝特对高脂血症的疗效。方法：对４０例高脂血症患者使用非诺贝特对高脂血症的疗效每日３００ｍｇ，疗程６个月，治疗前后检测血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、低密度脂蛋白－胆固醇（ＬＤＬ－Ｃ）、高密度脂蛋白－胆固醇（ＨＤＬ－Ｃ）和载脂蛋白Ａ－１、载脂蛋白Ｂ等。结果：ＴＧ平均降低了４５．２％，ＴＣ平均降低了２０．５％，ＨＤＬ－Ｃ平均上升１５．４％，ＬＤＬ－Ｃ平均降低了２５．５％，ａｐｏＡ     

小剂量辛伐他汀治疗高脂血症30例

目的 观察小剂量辛伐他汀治疗高旨血症的疗效。方法 高脂血症病人３０例,其中高胆固醇血症２９例,高甘油三酯血症１７例,ＨＤＬ－Ｃ低下者１４例,ＬＤＯ－Ｃ升高者２８例。每晚口服辛伐他汀１片,连服三个月。结果 ＴＣ,ＴＧ和ＬＤＬ－Ｃ分别下降３２％,２０％和３７％,ＨＤＬ－Ｃ升高２７％,在疗程中无严重副作用,追踪观察１／２－３年未发生心脑血管严重事件。     

国产小剂量洛伐他丁调脂疗效的临床观察

高脂血症作为冠心病（ＣＨＤ）的重要危险因素已得到肯定。降低血清总胆固醇（ＴＣ）水平可降低ＣＨＤ的患病率和病死率［１］，３羟３甲基戊二酰辅酶Ａ还原酶抑制剂是目前最有效的一类调脂药，国产洛伐他丁（罗华宁，ｌｏｖａｓｔａｔｉｎ），临床推荐剂量２０ｍｇ／ｄ。鉴于国内的高胆固醇血症多为中轻度，故本研究采用小剂量（１０ｍｇ／ｄ）洛伐他丁，以评价其调脂效果及安全性。１　临床材料１．１　研究对象　所有病例均系１９９７年１０月至１９９８年２月本院心内科住院病人，共３６例，男２１例，女１５例，年龄３６～７６（５…     

非诺贝特治疗高脂血症40例疗效观察

目的：观察非诺贝特对高脂血症的疗效。方法：对４０例高脂血症患者使用非诺贝特，每日３００ｍｇ，疗程６个月；治疗前后检测血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、低密度脂蛋白胆固醇（ＬＤＬＣ）、高密度脂蛋白胆固醇（ＨＤＬＣ）和载脂蛋白Ａ１（ａｐｏＡ１）、载脂蛋白Ｂ（ａｐｏＢ）等。结果：ＴＧ平均降低了４５．２％，ＴＣ平均降低了２０．５％，ＨＤＬＣ平均上升了１５．４％，ＬＤＬＣ平均降低了２５．５％，ａｐｏＡ１平均上升了２．０％，ａｐｏＢ平均下降了３０．０％。结论：非诺贝特具有降低ＴＧ、ＴＣ、ＬＤＬＣ、ａｐｏＢ和升高ＨＤＬＣ、ａｐｏＡ１作用，从而可减少冠状动脉粥样硬化性心脏病的发病率和病死率     

血清低密度脂蛋白胆固醇直接测定与Friedewald公式计算结果比较

总结了应用聚乙烯硫酸（ＰＶＳ）沉淀法测定１２３１例标本的低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）值并与Ｆｒｉｅｄｅｗａｌｄ公式计算的结果比较，按甘油三酯（ＴＧ）浓度分组，对比两法ＬＤＬ－Ｃ值的差异及影响ＬＤＬ－Ｃ值的因素。结果显示在低浓度ＴＧ时两法基本一致，高ＴＧ时两法差别较大。ＴＧ＞４．５２ｍｍｏｌ／Ｌ（４００ｍｇ／ｄｌ）时Ｆｒｉｅｄｅｗａｌｄ公式计算结果偏低。以直接测定ＬＤＬ－Ｃ值计算ＶＬＤＬ－Ｃ／ＴＧ比例平均为１：６．３，不同于Ｆｒｉｅｄｅｗａｌｄ公式中的１：５。     

异基因外周血干细胞移植治疗恶性血液病的临床研究

目的 评价异基因外周血干细胞移植（ａｌｌｏＰＢＳＣＴ） 治疗恶性血液病的疗效。方法 用异基因外周血干细胞移植治疗恶性血液病１６ 例,其中急性淋巴细胞白血病５ 例（ＣＲ１ ４ 例,ＣＲ２ １ 例） , 急性非淋巴细胞白血病２ 例（ＣＲ１） ,慢性粒细胞白血病８ 例（ＣＰ５ 例,ＡＰ３ 例） ,非霍奇金淋巴瘤１ 例（ＰＲ） 。中位年龄３３（１８ ～４９） 岁。预处理方案：ＴＢＩ９ ～１０ Ｇｙ（ 分２ 次照射） ＋ ＣＴＸ １２０ ｍ ｇ／ｋｇ 或ＴＢＩ１０Ｇｙ ＋ＣＴＸ１２０ ｍｇ／ｋｇ ＋ Ｖｐ１６ ５００ ｍｇ 。预防移植物抗宿主病（ ＧＶＨＤ） 方案：ＣｓＡ＋ 短程ＭＴＸ。供者年龄中位数３２（１４ ～５２） 岁, 用ＧＣＳＦ５μｇ ·ｋｇ － １ ·ｄ － １ ×５ ～６ 天进行造血干细胞动员, 分离单个核细胞中位数９ ×１０８／ｋｇ［５ ．７９ ～１３ ．７０） ×１０８／ｋｇ］ ,ＣＤ３４ ＋ 细胞中位数１３ ．９ ×１０６／ｋｇ［５ ．６９ ～４９ ．００） ×１０６／ ｋｇ］ 。结果全部患者移植后均重建造血,仅１ 例（ＡＢＯ 血型不合） 红系延迟重建。粒细胞＞ ０ ．５ ×１０９／ Ｌ 中位数１２（１０ ～１５） 天,血小板＞ ３０ ×１０９／Ｌ 中位数１３（８ ～２４） 天     

血脂与载脂蛋白关系研究

本文报告了８６１例血脂和载脂蛋白的检测结果。结果表明：高脂血者的ＡｐｏＡ－Ｉ和ＡｐｏＢ均增高，差异有显著性；相关分析表明，ＴＣ与ＡｐｏＡ－Ｉ、ＡｐｏＢ均呈显著正相关，ＴＣ、ＴＧ含量升高与ＡｐｏＡ－Ｉ／ＡｐｏＢ比值降低有高度一致性。由于ＡＰｏＢ和ＡｐｏＡ－Ｉ分别是ＬＤＬ和ＨＤＬ的主要蛋白质成分，而ＴＣ又是ＨＤＬ和ＬＤＬ的主要脂质成分，提示增大体内ＡｐｏＡ－Ｉ含量有利于提高血液中ＨＤＬ－ＴＣ水平，降低ＡｐｏＢ含量有利于降低体内ＬＤＬ－ＴＣ水平，这对预防高脂血症、冠心病、动脉粥样硬化等心脑血管疾病有重要意义，而利用ＡｐｏＡ－Ｉ／ＡｐｏＢ比值诊断高脂血症等疾病有重要的临床意义     

扩张型心肌病患者血清甘胆酸的动态分析

为探讨扩张型心肌病（ＤＣＭ）患者血清甘胆酸（ＣＧ）的变化，本文动态观察了２７例ＤＣＭ患者与３０例血型心肌病（ＩＣＭ）患者的血甭ＣＧ浓度及其他肝功能指标，结果：当心功能由Ⅳ级减轻至Ⅱ级（ＮＹＨＡ分级）时，ＤＣＭ组ＣＧ由１０．８２±．ｌｍｇ／Ｌ分别降至７．７７±２．５２ｍｇ／ｌ和３．３７±１．０５ｍｇ／Ｌ分别降至７．７７±１．０５ｍｇ／Ｌ；ＩＣＭ组ＸＣＧ由５．４６±１．２ｍｇ／Ｌ分别降至４．２３±０．     

术后短期使用ALG预防移植肾60例急性排斥反应的效应评估

目的：探索抗淋巴细胞球蛋白（ＡＬＧ）的合理使用方案。方法：随机选择肾移植患者６０例，根据使用ＡＬＧ的时间不同分两组，观察病人外周血ＣＤ３细胞数变化，急性排斥反应及并发症发生率，结果：两组病人急性排斥反应率，术后５天内ＣＤ３细胞数无统计学差异，但Ｂ组（ＡＬＧ３００ｍｇ／ｄ，７天以上）的巨细胞病毒病及一般感染率明显高于Ａ组（ＡＬＧ３００ｍｇ／ｄ，３～６天）结论：术后连续３～６天使用常规剂量ＡＬＧ是一种     

吉非罗剂对2型糖尿病血脂及血糖代谢的影响

目的：探讨吉非罗齐对２型糖尿病血脂、血糖代谢的影响。方法：在维持原糖尿病治疗方案的同时,将５１例２型糖尿病伴有高脂血症的患者分为２组。治疗组３１例予吉非罗齐胶囊４５０ｍｇ,每日２次口服,对照组２０例不服吉非罗齐。结果：治疗后３个月,治疗组总胆固醇（ＴＣ）、甘油三脂（ＴＧ）、低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）及空腹血糖（ＦＢＧ）均明显下降（Ｐ〈０．００１或Ｐ〈０．０１）,高密度脂蛋白胆固醇（ＨＤＬ－Ｃ     

辛伐他汀对急性冠脉综合征患者颈动脉粥样硬化的影响

目的：探讨辛伐他汀对急性冠脉综合征患者颈动脉粥样硬化的影响及其机制。方法：80例急性冠脉综合征患者随机分成辛伐他汀20 mg组（40例）和辛伐他汀40 mg组（40例）,于治疗前及治疗6个月后分别测定血清总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇（HDL-C）水平,并超声检测颈动脉内-中膜厚度（IMT）及颈动脉斑块面积。结果：两组治疗后TC、TG、LDL-C水平均明显降低（P〈0.01）,HDL-C明显升高（P〈0.01）;而辛伐他汀40 mg组较20 mg组作用更为明显（P〈0.05）。治疗6个月后IMT及颈动脉斑块面积明显缩小（P〈0.01）,且辛伐他汀40 mg组作用更显著（P〈0.01）。结论：辛伐他汀对急性冠脉综合征患者颈动脉粥样硬化斑块具有延缓和稳定作用。     

低剂量CT灌注在中度重症高血脂性急性胰腺炎转归中的评价价值

  目的  探讨低剂量CT灌注在中度重症高血脂性急性胰腺炎患者转归中临床意义。  方法  回顾性分析76例高血脂性胰腺炎患者CT灌注特点，其中中度重症（A组）54例，轻症（B组）22例。采用第三代西门子双源Force CT进行胰腺灌注扫描，将灌注图像传至工作站灌注软件包，对灌注参数血容量、血流量、流量提取乘积、平均通过时间、达峰时间、最大密度值进行组间比较，并分析实验室数据包括血淀粉酶、血脂肪酶、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、血糖、载脂蛋白A1、载脂蛋白B及灌注参数与临床分级的相关性。  结果  和B组相比，A组的总胆固醇，甘油三酯、高密度脂蛋白、平均通过时间、TTD均升高，灌注参数血容量、血流量、最大密度值、流量提取乘积均表现为降低（P < 0.05），胰腺灌注参数(灌注参数血容量、血流量、最大密度值)与高血脂性胰腺炎严重程度呈负相关（r=-0.835、-0.753、-0.543，P < 0.05）。  结论  第三代双源低剂量CT灌注可以用于评价高血脂性胰腺炎患者胰腺微循环障碍的严重程度，有利于临床早期治疗、干预。      

辛伐他汀对不稳定型心绞痛患者血清sCD40L水平的影响

目的：探讨辛伐他汀对不稳定型心绞痛患者血清中可溶性CD40L（sCD40L）水平的影响。方法：48例ACS患者随机分为2组：A组（安慰剂组）,B组（辛伐他汀组）。采用间接免疫荧光流式细胞术和酶联免疫吸附法（ELISA）及常规酶法分别测定2组患者用药前与用药2、4和6周后血清sCD40L含量及总胆固醇（TC）水平。结果：B组患者服药2、4及6周后血清sCD40L含量明显低于A组（P〈0.05,P〈0.01,P〈0.01）。B组患者服药2、4及6周后血清sCD40L含量呈逐渐下降趋势,同用药前相比均有显著性差异（P〈0.05,P〈0.01,P〈0.01）。B组患者服药2、4及6周后血浆TC含量与用药前相比均有统计学意义（P〈0.05,P〈0.01,P〈0.01）。B组患者血清sCD40L水平的降低与血浆TC含量的降低无明显相关性（P〉0.05）。结论：他汀类药物能明显降低不稳定型心绞痛患者体内sCD40L的水平,对减轻炎症反应、稳定斑块有一定作用。     

血糖调节异常者血脂代谢的初步研究

目的初步评价血糖调节受损患者血脂代谢异常情况。方法检测糖耐量正常(NGT)、单纯空腹血糖异常(IFG)、单纯糖耐量异常(IGT)、空腹血糖异常合并糖耐量异常(IFG IGT)和糖尿病(DM)患者空腹血糖和餐后2 h血糖及空腹血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A-I(apo A-I)和载脂蛋白B(apo B)水平,计算非高密度脂蛋白胆固醇(non-HDL-C)和血浆致动脉硬化指数(AIP),比较各组间血清脂质成分的差异。结果IFG组血清TC、LDL-C、non-HDL-C和apo B水平较NGT组明显升高(P<0.01),而TG、HDL-C、AIP差异无统计学意义(P>0.05)。IGT组血清TC、TG、LDL-C、non-HDL-C、apo A-I、apo B和AIP水平较NGT组显著升高(P<0.01),前6项指标与IFG IGT组差异无统计学意义(P>0.05)。IFG IGT组与NGT组比较,各指标差异均有统计学意义(P<0.01);HDL-C、non-HDL-C和AIP水平与IFG组比较差异有统计学意义(P<0.01)。DM组表现出典型的DM性脂代谢紊乱伴AIP水平显著异常。non-HDL-C和apo B间存在良好的相关性(P<0.01)。结论血糖调节受损者不同程度的存在血脂代谢异常,主要表现为TC、TG、LDL-C、non-HDL-C和apo B水平的升高和HDL-C、apo A-I的降低,伴不同程度AIP水平的改变。     

Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.

BACKGROUND: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. OBJECTIVE: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. METHODS: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. RESULTS: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P < 0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P < 0.001 vs baseline) in the simvastatin group and by 4.3% (P < 0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P < 0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). CONCLUSIONS: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.     

Effect of simvastatin on apoprotein B—containing lipoproteins in patients with diabetic nephropathy

Background: Diabetic patients with nephropathy usually have a more atherogenic lipoprotein profile than those without nephropathy, which may be associated with the substantially higher incidence of coronary heart disease (CHD) in this population. Simvastatin has been shown to significantly reduce the incidence of CHD events in diabetic patients.Objective: The purpose of this study was to evaluate the effect of simvastatin (10 mg/d) on atherogenic apoprotein (apo) B—containing lipoproteins in type 2 diabetic patients with nephropathy.Methods: Diabetic patients with nephropathy and a group of healthy control subjects matched for age, sex, and body weight were enrolled. Diabetic patients were administered simvastatin 10 mg/d for 6 months. Apo B—containing lipoproteins were sequentially separated by ultracentrifugation to yield very low-density lipoprotein (VLDL) (density <1.006 g/mL), intermediate-density lipoprotein (IDL) (1.006-1.019 g/mL), light low-density lipoprotein (LDL) (1.019-1.044 g/mL), and dense LDL (1.044-1.063 g/mL) fractions. Apo B in lipoproteins was measured by a sensitive enzyme-linked immunosorbent assay at baseline and after 6 months of simvastatin treatment.Results: A total of 18 patients with diabetic nephropathy and 36 matched controls were enrolled. The diabetic patients had significantly higher levels (P < 0.01) of total cholesterol, LDL cholesterol, triglycerides, and apo B compared with age- and weight-matched control subjects at baseline. The diabetic patients also had significantly higher levels (P < 0.05) of cholesterol and apo B in the VLDL, light LDL, and dense LDL fractions. Treatment with simvastatin for 6 months significantly reduced plasma total cholesterol by 21%, LDL cholesterol by 30%, and apo B by 25% (P < 0.001), but did not affect urinary albumin excretion. Simvastatin significantly decreased both triglyceride and cholesterol levels in VLDL by 18% (P < 0.05), and cholesterol and apo B in IDL by 22% (P < 0.05) and 26% (P < 0.01). Simvastatin decreased both the light and dense LDL subfractions to a similar extent, reducing cholesterol and apo B in light LDL by 27% (P < 0.001) and in dense LDL by 28% (P < 0.01) and 18% (P < 0.05), respectively. The light LDL/dense LDL ratio for apo B and for cholesterol were not altered by simvastatin therapy.Conclusions: The results of this study suggest that simvastatin may reduce levels of atherogenic apo B—containing lipoproteins and small dense LDL in diabetic patients with nephropathy.     

原发性甲状腺功能亢进症患者血尿酸相关性研究

【目的】探讨原发性甲状腺功能亢进症（甲亢）患者血尿酸（UA）与甲状腺功能水平的相关性。【方法】收集原发性甲亢患者61例,按照血 UA 水平（男性＞420μmol／L ,女性＞360μmol／L ）分为高尿酸血症（ HUA）组、正常尿酸血症（ NUA）组,另外收集同期年龄和性别匹配的健康体检人群作为健康对照组,检测并比较三组甲状腺功能指标[游离三碘甲腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH ）水平]、空腹血糖（FBS）、肾功能指标[尿素氮（BUN）、肌酐（Cr）、UA ];肝功能[丙氨酸基转移酶（ALT ）和天冬氨酸氨基转移酶（AST ）]、血脂[三酰甘油（TG）、胆固醇（TC）、高密度脂蛋白（HDL‐C）、低密度脂蛋白（LDL‐C）],分析 UA 与甲状腺功能水平的相关性。【结果】NUA 组 FT3、FT4均明显高于对照组（P ＜0．01）,而 TC 、HDL‐C 、LDL‐C 、TSH 均明显低于对照组（P ＜0．01）,但两组 FBS 、AST 、TG 、BUN 、Cr 、UA 比较差异无统计学意义（P ＞0．05）。与 NUA 组比较,HUA 组 BUN 、UA 、Cr 、FT3、FT4明显升高（P ＜0．05）,TSH 水平明显下降,其差异均有统计学意义（P ＜0．05）;而两组 FBS 、ALT 、AST 、TG 、TC 、HDL‐C 、LDL‐C 比较差异无统计学意义（P ＞0．05）。 UA 与 FT3、FT4呈正相关（P ＜0．05）,与 TSH 呈负相关（P ＜0．05）,血清 Cr 与 FT3、FT4呈负相关（P ＜0．05）。【结论】原发性甲亢患者易合并血 UA 升高,血 UA 水平与患者的高甲状腺激素水平密切相关。     

高尿酸血症与2型糖尿病合并血管并发症的相关性研究

目的探讨高尿酸血症和合并2型糖尿病患者血管并发症的相关危险因素。方法选取体检健康者97例纳入对照组,单纯2型糖尿病组103例和2型糖尿病合并高尿酸血症组78例。比较3组受试者空腹血糖(FPG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白(Apo)A1、ApoB、肌酐(Cr)、尿酸(UA),同时留取晨尿检测尿微量清蛋白(UMA)及体质量指数(BMI),并研究高尿酸血症和糖尿病相关并发症的相关性。结果单纯2型糖尿病组FPG、TG、Cr、UMA、HbA1c水平均高于对照组(P0.05);2型糖尿病合并高尿酸血症组BMI、FPG、TG、TC、LDL-L、UMA、Cr、HbA1c均高于对照组(P0.05);2型糖尿病合并高尿酸血症组BMI、TG、Cr、UMA、HbA1c均高于单纯2型糖尿病组(P0.05)。2型糖尿病合并高尿酸血症组患者的糖尿病肾病、下肢动脉斑块发病率明显高于单纯2型糖尿病组,差异有统计学意义(P0.05)。结论 2型糖尿病合并高尿酸血症组患者比单纯2型糖尿病患者更易发生血脂异常,2型糖尿病合并高尿酸血症组患者糖尿病肾病、下肢动脉斑块发病率也明显高于单纯2型糖尿病患者。     

A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia

BACKGROUND: Pitavastatin is a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor used to treat hypercholesterolemia. OBJECTIVE: The goal of this study was to compare the efficacy and safety of pitavastatin versus those of simvastatin in Korean patients with hypercholesterolemia. METHODS: This was an 8-week, multicenter, prospective, randomized, open-label, Phase III clinical trial. Male and female Korean patients with hypercholesterolemia who were between the ages of 20 and 75 years and who had a fasting triglyceride level <600 mg/dL and a low-density lipoprotein (LDL) cholesterol level >130 mg/dL after a 4-week dietary lead-in period were eligible for entry. Eligible patients were randomized into 2 groups in a 1:1 ratio. Patients received pitavastatin 2 mg once daily or simvastatin 20 mg once daily for 8 weeks. The medication was administered initially for 4 weeks, and an additional 4 weeks of study medication was prescribed at week 4. The final visit was conducted 8 weeks after randomization. RESULTS: Of the 104 patients randomized to treatment, 95 patients (59 women; 36 men) completed the study (49 in the pitavastatin group [mean age, 59.9 years] and 46 in the simvastatin group [mean age, 56.4 years]). No significant difference was found between groups with respect to patient age, sex, or body mass index. There was no significant difference in the percent decrease in LDL cholesterol levels (mean [SD], 38.2% [11.6%] decrease for the pitavastatin group vs 39.4% [12.9%] decrease for the simvastatin group [P = 0.648]). Also, there were no significant differences between the 2 study groups in the percent changes in total cholesterol, triglyceride, or high-density lipoprotein (HDL) cholesterol levels from baseline to study end. No significant difference was observed for the proportion of patients who achieved the LDL cholesterol goal of the National Cholesterol Education Program Adult Treatment Panel III: 93.9% (46/49) of patients in the pitavastatin group and 91.3% (42/46) of patients in the simvastatin group (P = 0.709) met the target level. At least 1 clinical adverse event and at least 1 adverse drug reaction were observed in 25.0% (13/52) and 11.5% (6/52), respectively, of patients in the pitavastatin group, and 37.3% (19/51) and 23.5% (12/51), respectively, in the simvastatin group; this difference was not statistically significant. The most common adverse event was an elevation in creatine kinase levels >2 times the upper limit of normal in 3.8% of pitavastatin-treated patients and 9.8% of simvastatin-treated patients (P = 0.269). There were no serious adverse drug reactions observed in either group. CONCLUSION: The HMG-CoA reductase inhibitor pitavastatin was found to be noninferior to simvastatin in terms of reducing LDL cholesterol, total cholesterol, and triglyceride levels, and increasing HDL cholesterol levels, in Korean patients with hypercholesterolemia after 8 weeks of treatment.     

糖耐量受损的冠心病患者血浆同型半胱氨酸和血脂水平的变化

目的探讨糖耐量受损的冠心病患者血浆总同型半胱氨酸（tHcy）和血脂水平的变化。方法采用高效液相层析技术测定45例糖耐量受损的冠心病患者（糖耐量受损组）和51例糖耐量正常的冠心病患者（糖耐量正常组）血浆tHcy水平,同时测定常规血脂。结果糖耐量受损组血浆tHcy、总胆固醇（TC）、载脂蛋白B（apo B）、低密度脂蛋白胆固醇（LDL-C）、水平高于糖耐量正常组（P〈0.05、P〈0.01）;而三酰甘油（TG）、载脂蛋白A-I（apo A-I）、高密度脂蛋白胆固醇（HDL-C）2组差异无统计学意义（P〉0.05）。tHcy水平和患者年龄、apo A-I相关（P〈0.05）,而与其他血脂指标不相关（P〉0.05）。结论血浆tHcy水平的增高与糖耐量受损和冠心病的发生密切相关。